These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 36561983)

  • 1. The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy.
    Shu CL; Liu YL
    Cancer Manag Res; 2022; 14():3485-3492. PubMed ID: 36561983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
    Santarpia M; Ciappina G; Spagnolo CC; Squeri A; Passalacqua MI; Aguilar A; Gonzalez-Cao M; Giovannetti E; Silvestris N; Rosell R
    Transl Lung Cancer Res; 2023 Feb; 12(2):346-368. PubMed ID: 36895930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.
    Karachaliou A; Kotteas E; Fiste O; Syrigos K
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
    Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
    Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting KRAS in Non-Small Cell Lung Cancer.
    Corral de la Fuente E; Olmedo Garcia ME; Gomez Rueda A; Lage Y; Garrido P
    Front Oncol; 2021; 11():792635. PubMed ID: 35083149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes.
    Palma G; Khurshid F; Lu K; Woodward B; Husain H
    NPJ Precis Oncol; 2021 Nov; 5(1):98. PubMed ID: 34845311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to manage
    Ricciuti B; Mira A; Andrini E; Scaparone P; Michelina SV; Pecci F; Cantini L; De Giglio A; Lamberti G; Ambrogio C; Metro G
    Drugs Context; 2022; 11():. PubMed ID: 36452878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.
    Spagnuolo A; Maione P; Gridelli C
    Transl Lung Cancer Res; 2022 Jun; 11(6):1199-1216. PubMed ID: 35832439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.
    Li JX; Li RZ; Ma LR; Wang P; Xu DH; Huang J; Li LQ; Tang L; Xie Y; Leung EL; Yan PY
    Front Pharmacol; 2022; 13():875330. PubMed ID: 35517800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking the 'Undruggable' Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with
    Chmielewska I; Krawczyk P; Grenda A; Wójcik-Superczyńska M; Krzyżanowska N; Gil M; Milanowski J
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509393
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current status and outlook of medical treatment for
    Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup.
    Xie M; Xu X; Fan Y
    Front Oncol; 2021; 11():672612. PubMed ID: 34012925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
    Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
    Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting KRAS in Colorectal Cancer.
    Wang C; Fakih M
    Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.